CoChat

Clinical Pharmacology Considerations in Pain Management in Patients with Advanced Kidney Failure

Open access
Davison, Sara N. · 2019 · Clinical Journal of the American Society of Nephrology
Cited by 123

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Pain is common and poorly managed in patients with advanced CKD, likely due to both under and over prescription of appropriate analgesics. Poorly managed pain contributes to patients’ poor quality of life and excessive health care use. There is tremendous variability within and between countries in prescribing patterns of analgesics, suggesting that factors other than patient characteristics account for these differences. This article discusses the pharmacologic management of acute and chronic pain in patients with advanced CKD, and the role analgesics, including opioids, play in the overall approach to pain management.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2215/cjn.05180418

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 51

  1. Davison, 2014, Pain in chronic kidney disease: A scoping review, Semin Dial, 27, 188, 10.1111/sdi.12196 · DOI · Paper page
  2. Davison, 2006, Longitudinal validation of a modified Edmonton symptom assessment system (ESAS) in haemodialysis patients, Nephrol Dial Transplant, 21, 3189, 10.1093/ndt/gfl380 · DOI · Paper page
  3. Davison, 2005, The impact of chronic pain on depression, sleep, and the desire to withdraw from dialysis in hemodialysis patients, J Pain Symptom Manage, 30, 465, 10.1016/j.jpainsymman.2005.05.013 · DOI · Paper page
  4. Cohen, 2007, Pain, sleep disturbance, and quality of life in patients with chronic kidney disease, Clin J Am Soc Nephrol, 2, 919, 10.2215/CJN.00820207 · DOI · Paper page
  5. Davison, 2010, Impact of pain and symptom burden on the health-related quality of life of hemodialysis patients, J Pain Symptom Manage, 39, 477, 10.1016/j.jpainsymman.2009.08.008 · DOI · Paper page
  6. Weisbord, 2014, Associations of depressive symptoms and pain with dialysis adherence, health resource utilization, and mortality in patients receiving chronic hemodialysis, Clin J Am Soc Nephrol, 9, 1594, 10.2215/CJN.00220114 · DOI
  7. Barnard, 2006, Pain management in palliative care, S Afr Fam Pract, 48, 30, 10.1080/20786204.2006.10873406 · doi:10.1080/20786204.2006.10873406
  8. Barakzoy, 2006, Efficacy of the world health organization analgesic ladder to treat pain in end-stage renal disease, J Am Soc Nephrol, 17, 3198, 10.1681/ASN.2006050477 · DOI · Paper page
  9. Wilkerson, 2016, The opioid epidemic in the United States, Emerg Med Clin North Am, 34, e1, 10.1016/j.emc.2015.11.002 · DOI · Paper page
  10. Rolita, 2013, Greater number of narcotic analgesic prescriptions for osteoarthritis is associated with falls and fractures in elderly adults, J Am Geriatr Soc, 61, 335, 10.1111/jgs.12148 · DOI · Paper page
  11. Ishida, 2018, Opioid analgesics and adverse outcomes among hemodialysis patients, Clin J Am Soc Nephrol, 13, 746, 10.2215/CJN.09910917 · DOI
  12. Nagar, 2017, Opioid use in chronic pain patients with chronic kidney disease: A systematic review, Pain Med, 18, 1416, 10.1093/pm/pnw238 · DOI
  13. Kimmel, 2017, Opioid prescription, morbidity, and mortality in United States dialysis patients, J Am Soc Nephrol, 28, 3658, 10.1681/ASN.2017010098 · DOI · Paper page
  14. Evans, 2009, Acetaminophen, aspirin and progression of advanced chronic kidney disease, Nephrol Dial Transplant, 24, 1908, 10.1093/ndt/gfn745 · DOI · Paper page
  15. Wongrakpanich, 2018, A comprehensive review of non-steroidal anti-inflammatory drug use in the elderly, Aging Dis, 9, 143, 10.14336/AD.2017.0306 · DOI · Paper page
  16. Moore, 1998, Quantitative systematic review of topically applied non-steroidal anti-inflammatory drugs, BMJ, 316, 333, 10.1136/bmj.316.7128.333 · DOI · Paper page
  17. Massey, 2010, Topical NSAIDs for acute pain in adults, Cochrane Database Syst Rev, 16, CD007402
  18. Sande, 2017, The use of opioids in cancer patients with renal impairment-a systematic review, Support Care Cancer, 25, 661, 10.1007/s00520-016-3447-0 · DOI
  19. Sarton, 2008, Naloxone reversal of opioid-induced respiratory depression with special emphasis on the partial agonist/antagonist buprenorphine, Adv Exp Med Biol, 605, 486, 10.1007/978-0-387-73693-8_85 · DOI
  20. McQuay, 1996, A systematic review of antidepressants in neuropathic pain, Pain, 68, 217, 10.1016/S0304-3959(96)03140-5 · DOI · Paper page
  21. Atalay, 2013, Cross-over, open-label trial of the effects of gabapentin versus pregabalin on painful peripheral neuropathy and health-related quality of life in haemodialysis patients, Clin Drug Investig, 33, 401, 10.1007/s40261-013-0080-2 · DOI
  22. Ibrahim, 2017, Treatment of gabapentin toxicity with peritoneal dialysis: Assessment of gabapentin clearance, Am J Kidney Dis, 70, 878, 10.1053/j.ajkd.2017.05.010 · doi:10.1053/j.ajkd.2017.05.010
  23. Varney, Detecting aberrant opioid behavior in the emergency department: A prospective study using the screener and Opioid Assessment for Patients with Pain-Revised (SOAPP®-R), Current Opioid Misuse Measure (COMM)™, and provider gestalt [published online ahead of print March 3, 2018], Intern Emerg Med
  24. 2016, “Weak” opioid analgesics. Codeine, dihydrocodeine and tramadol: No less risky than morphine, Prescrire Int, 25, 45
  25. Gunter, 2017, Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: A meta-analysis, J Clin Pharm Ther, 42, 27, 10.1111/jcpt.12484 · DOI
  26. Gibson, 1980, Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient, Clin Pharmacol Ther, 27, 665, 10.1038/clpt.1980.94 · DOI
  27. Raffa, 1992, Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an ‘atypical’ opioid analgesic, J Pharmacol Exp Ther, 260, 275
  28. Smith, 2009, Opioid metabolism, Mayo Clin Proc, 84, 613, 10.1016/S0025-6196(11)60750-7 · DOI · Paper page
  29. Quigley, 2003, Plasma concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with cancer-related pain, Palliat Med, 17, 185, 10.1191/0269216303pm658oa · doi:10.1191/0269216303pm658oa
  30. Kirvela, 1996, The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation, J Clin Anesth, 8, 13, 10.1016/0952-8180(95)00092-5 · DOI
  31. Foral, 2007, Oxycodone accumulation in a hemodialysis patient, South Med J, 100, 212, 10.1097/01.smj.0000242876.45747.0a · doi:10.1097/01.smj.0000242876.45747.0a
  32. Malhotra, 2015, The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment, J Opioid Manag, 11, 157, 10.5055/jom.2015.0265 · doi:10.5055/jom.2015.0265
  33. Lee, 2005, Measurements of plasma oxycodone, noroxycodone and oxymorphone levels in a patient with bilateral nephrectomy who is undergoing haemodialysis, Palliat Med, 19, 259, 10.1191/0269216305pm1004cr · doi:10.1191/0269216305pm1004cr
  34. Samolsky Dekel, 2017, Dialyzability of oxycodone and its metabolites in chronic noncancer pain patients with end-stage renal disease, Pain Pract, 17, 604, 10.1111/papr.12483 · doi:10.1111/papr.12483
  35. Darwish, 2016, Effects of renal impairment and hepatic impairment on the pharmacokinetics of hydrocodone after administration of a hydrocodone extended-release tablet formulated with abuse-deterrence technology, Clin Pharmacol Drug Dev, 5, 141, 10.1002/cpdd.238 · doi:10.1002/cpdd.238
  36. Kreek, 1980, Methadone use in patients with chronic renal disease, Drug Alcohol Depend, 5, 197, 10.1016/0376-8716(80)90180-5 · DOI
  37. Hand, 1990, Buprenorphine disposition in patients with renal impairment: Single and continuous dosing, with special reference to metabolites, Br J Anaesth, 64, 276, 10.1093/bja/64.3.276 · DOI
  38. Chiang, 2003, Pharmacokinetics of the combination tablet of buprenorphine and naloxone, Drug Alcohol Depend, 70, S39, 10.1016/S0376-8716(03)00058-9 · DOI · Paper page
  39. Filitz, 2006, Effects of intermittent hemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine, Eur J Pain, 10, 743, 10.1016/j.ejpain.2005.12.001 · DOI
  40. Dole, 1973, Methadone plasma level: Sustained by a reservoir of drug in tissue, Proc Natl Acad Sci USA, 70, 10, 10.1073/pnas.70.1.10 · DOI
  41. Perlman, 2013, Intradialytic clearance of opioids: Methadone versus hydromorphone, Pain, 154, 2794, 10.1016/j.pain.2013.08.015 · doi:10.1016/j.pain.2013.08.015
  42. Joh, 1998, Nondialyzability of fentanyl with high-efficiency and high-flux membranes, Anesth Analg, 86, 447, 10.1213/00000539-199802000-00049 · doi:10.1213/00000539-199802000-00049
  43. Opdal, 2015, Effects of hemodialysis on methadone pharmacokinetics and QTc, Clin Ther, 37, 1594, 10.1016/j.clinthera.2015.04.009 · doi:10.1016/j.clinthera.2015.04.009
  44. Furlan, 1999, Methadone is poorly removed by haemodialysis, Nephrol Dial Transplant, 14, 254, 10.1093/ndt/14.1.254 · DOI
  45. Randinitis, 2003, Pharmacokinetics of Pregabalin in Subjects with Various Degrees of Renal Function, J Clin Pharmacol, 43, 277, 10.1177/0091270003251119 · DOI · Paper page
  46. Bockbrader, 2010, A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin, Clin Pharmacokinet, 49, 661, 10.2165/11536200-000000000-00000 · DOI · Paper page
  47. Randinitis, 2003, Pharmacokinetics of pregabalin in subjects with various degrees of renal function, J Clin Pharmacol, 43, 277, 10.1177/0091270003251119 · DOI · Paper page
  48. Lee, 1980, Hemodialysis clearance and total body elimination of carbamazepine during chronic hemodialysis, Clin Toxicol, 17, 429, 10.3109/15563658008989993 · doi:10.3109/15563658008989993
  49. Gupta, 1999, Pharmacokinetic and pharmacodynamic characterization of OROS and immediate-release amitriptyline, Br J Clin Pharmacol, 48, 71, 10.1046/j.1365-2125.1999.00973.x · DOI
  50. Sandoz, 1984, Metabolism of amitriptyline in patients with chronic renal failure, Eur J Clin Pharmacol, 26, 227, 10.1007/BF00630290 · doi:10.1007/bf00630290
  51. Bell, 2009, Ketamine for chronic non-cancer pain, Pain, 141, 210, 10.1016/j.pain.2008.12.003 · DOI · Paper page

Cited by

See all 123

Metadata

Authors
Davison, S. N.
Venue
Clinical Journal of the American Society of Nephrology
Published
2019-03-04
Volume
14
Issue
6
Pages
917-931
ISSN
  • 1555-9041 (ISSN-L)
  • 1555-905X
OpenAlex
W2919576556
Cited by
123
References
4
FWCI
22.82
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.